This is a preview of subscription content, log in via an institution to check access.
Notes
The analysis was funded by sanofi-aventis, US; two of the researchers are employees of that company.
A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from any Cause in PatiENts with Atrial Fibrillation/Atrial Flutter
Reference
Reynolds MR, et al. Estimation of Potential Cost Savings Associated With Reduced Rates of Cardiovascular Hospitalization Among Atrial Fibrillation/Flutter Patients Treated With Dronedarone in the ATHENA Trial. American Journal of Therapeutics : 23 Jan 2013. Available from: URL: http://dx.doi.org/10.1097/MJT.0b013e31826fc43c
Rights and permissions
About this article
Cite this article
Dronedarone saves hospitalisation costs. PharmacoEcon Outcomes News 671, 6 (2013). https://doi.org/10.1007/s40274-013-0133-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0133-z